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Angiotensin II type 1 receptor gene polymorphism predicts progression of cardiac and renal disease [1–6]. Most of
response to losartan and angiotensin II. the known actions of Ang II are mediated by the Ang II
Background. Most of the known actions of angiotensin II type 1 receptor (AGT1R) [7], including vascular contrac-(Ang II) are mediated by the Ang II type 1 receptor (AGT1R).
tion, pressor responses, proximal tubule sodium trans-A noncoding polymorphism of the AGT1R gene has been de-
port, and aldosterone secretion. The receptor is ex-scribed in which there is either an adenine (A) or cytosine
(C) base at position 1166. The functional significance of this pressed on the surface of a variety of cell types, including
polymorphism is unknown, prompting us to examine the rela- vascular smooth muscle cells and myocardial cells, as
tionship between this polymorphism and the systemic and renal well as vascular smooth muscle cells of the afferent andresponses to AGT1R blockade and subpressor Ang II infusion.
efferent arterioles, mesangial cells and proximal tubuleMethods. Sixty-six healthy Caucasian men and women, ge-
cells of the kidney, and the glomerulosa cells of thenotyped for the AGT1R polymorphism by polymerase chain
reaction, were chosen to form two homogeneous groups: AA adrenal gland [8].
and AC/CC. Renal hemodynamic function was assessed with Recently, a polymorphism of the AGT1R gene hasinulin and para-aminohippurate clearance before and after
been described in which there is either an adenine (A) orAGT1R receptor blockade with losartan and Ang II infusion.
cytosine (C) base at position 1166 in the 39 untranslatedResults. The mean values at baseline for glomerular filtra-
tion rate (GFR), renal plasma flow (ERPF), and renal blood region of the gene [9]. Epidemiological studies have re-
flow (RBF) were significantly lower in the AC/CC group com- vealed an association between this noncoding polymor-
pared with the AA group. Losartan increased the GFR and phism and hypertension [9] and aortic stiffness in hyper-
decreased the mean arterial pressure (MAP) in the AC/CC
tensive patients [10]. There may also be a synergisticgroup, but did not influence these parameters in the AA group.
interaction between the AGT1R polymorphism and theThe aldosterone responses to losartan were blunted in the AA
subgroup. During Ang II infusion, AC/CC subjects maintained angiotensin-converting enzyme (ACE) insertion/dele-
GFR despite equivalent declines in RBF, suggesting an en- tion polymorphism on the risk of myocardial infarction
hanced efferent arteriolar constrictive response. [11]. In contrast, other case control studies have failedConclusions. Taken together, these results suggest that there
to establish significant associations between the AGT1Ris a relationship between the AGT1R A1166→C polymorphism
polymorphism and endpoints such as diabetic microangi-and the humoral and renal hemodynamic responses to AGT1R
blockade and to Ang II infusion in the sodium-replete state, opathy [12].
and that the C allele is associated with enhanced intrarenal Because the AGT1R A1166→C polymorphism is in anand peripheral Ang II activity. Further studies are required to untranslated region of the gene, the functional signifi-determine the genetic locus for this effect.
cance of the polymorphism is unclear, although Amant et
al have recently reported that methylergonovine induces
more coronary artery vasoconstriction in patients withThe activation of the renin-angiotensin system (RAS)
at least one copy of the C allele compared with patientsand the subsequent generation of angiotensin II (Ang II)
homozygous for the A allele [13]. We first hypothesizedplay important roles in both normal physiology and the
that there would be an association between the AGT1R
polymorphism and renal and systemic hemodynamic
1 See Editorial by Blantz, p. 2317 function. This hypothesis was tested by comparing base-
line function in normal healthy male and premenopausalKey words: glomerular filtration rate, renal blood flow, mean arterial
pressure, aldosterone, losartan, angiotensin II. female subjects ingesting a controlled sodium and pro-
tein diet and grouped according to the AGT1R A1166→CReceived for publication October 27, 1998
polymorphism. A sodium intake of approximately 200and in revised form July 10, 1999
Accepted for publication July 19, 1999 mmol/day was chosen so that all subjects were sodium
replete, thus avoiding RAS activation and ensuring a 1999 by the International Society of Nephrology
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uniform response to our interventions. We further hy- end of this period, losartan (Cozaart; Merck, Sharpe,
and Dohne, Hamburg, Germany) was administered at apothesized that renal and systemic Ang II activity would
be augmented in subjects with the C allele. We tested subdepressor dose of 25 mg. During each hour for three
hours, blood was collected for inulin and PAH, hemato-this hypothesis by comparing hemodynamic and humoral
responses to AGT1R blockade with losartan and with crit (Hct), and aldosterone, and urine was collected for
inulin, PAH, and sodium.low-dose subpressor infusions of Ang II.
Part 2. On the second day of the protocol, a minimum
of one week later, the subjects reported to the renal
METHODS
physiology laboratory, having again followed the sodi-
Subjects um- and protein-controlled diet, and collected a 24-hour
urine. As in part 1, subjects were studied while supine,Sixty-six normal healthy males and females were re-
cruited to participate in the study. Their mean age was in a warm quiet room, after an overnight fast. Inulin and
PAH were infused, and three timed urine collections28 6 1 years (range 20 to 35 years). Each subject under-
went a detailed history and physical examination by a were obtained. At the end of this baseline period, blood
samples were obtained for Hct, inulin, and PAH, andqualified internist. All were Caucasian, normotensive
and nonobese, and nonsmokers and were on no medica- aldosterone. A solution of Ang II (Hypertensint; 2.5
mg/vial; Ciba Geigy Canada, Ltd., Mississauga, Ontario,tions. They were subdivided on the basis of the presence
of the C allele, and thus, two homogeneous groups (AA, Canada) was prepared by dissolving the diluent in nor-
mal saline to produce a concentration of 0.5 mg/ml. TwoN 5 30, and AC/CC, N 5 36) were formed for these
experiments. The study was performed with the approval hundred and fifty milliliters of normal saline were there
added to 0.2 ml Ang II to produce a concentration ofof the University of Toronto Human Subjects Review
Committee and with the informed written consent of 400 ng/ml. Ang II was infused at a subpressor dose of
0.5 ng/kg/min for 30 minutes. Subjects remained supineeach subject.
All subjects were counseled to adhere to a diet that except to void. Blood was collected once at the end of
the infusion period for inulin and PAH, aldosterone, andmaintained their normal caloric intake, their sodium in-
take to 200 mmol/day, and their protein intake to 1.5 to Hct, and urine was collected for sodium, inulin, and
PAH. MAP was also measured at the midpoint of each2 g/kg/day for seven days prior to each study day. A 24-
hour urine sample was obtained one day prior to each infusion. A further collection of both blood and urine
was obtained at the end of the Ang II infusion after astudy for the measurement of sodium and urea excretion
to assess compliance with the controlled diet. On the 30-minute recovery period.
day of the testing, the volunteer subjects reported to the
Sample collection and analytical methodsrenal physiology laboratory. All studies were conducted
at 8:30 a.m. after an overnight fast, with the subjects Blood samples collected for inulin and PAH determi-
nations were immediately centrifuged at 3000 r.p.m. forlying supine in a warm quiet room.
10 minutes at 48C. Plasma was separated, placed on ice,
Study protocol and then stored at 2708C before the assay. Inulin concen-
trations in plasma and urine were measured by a modi-Part 1. On the first day of the protocol, an 18-gauge
peripheral venous cannula was inserted into an antecubi- fied method of Walser, Davidson, and Orloff [15], and
the PAH concentration was measured by a spectropho-tal vein for infusions of inulin and para-aminohippuric
acid (PAH), and a second cannula was inserted in the tometric method according to Brun [16]. The mean of the
final two clearance periods represent GFR and ERPF,contralateral arm for blood sampling. Each subject
voided and then drank 800 ml water in the first 45 min- expressed per 1.73 m2. Filtration fraction (FF) repre-
sented the ratio of GFR to ERPF. Renal blood flowutes to induce a water diuresis. Two hundred milliliters
were ingested in each hour of the protocol to maintain (RBF) was calculated by dividing the ERPF by (1 2
Hct). Renal vascular resistance (RVR) was derived byan adequate urine output for collection of spontaneously
voided samples. Hemodynamic parameters [mean arte- dividing MAP by the RBF.
The serum sodium concentration was measured by anrial pressure (MAP), heart rate] were measured through-
out the study by an automated sphygmomanometer (Di- ion-selective electrode method and urine sodium by a
flame photometry method. Aldosterone was measurednamapp) and were recorded once in each half hour of
the protocol. Renal hemodynamics were measured using by radioimmunoassay, using the Coat-A-Count system.
Serum ACE activity was measured by a spectrophoto-inulin and PAH clearance techniques, as previously de-
scribed [14]. Three timed urine collections of 20 minutes’ metric method using an ACE kinetic test kit (Buhlmann
Laboratories AG, Schonembuch, Switzerland). Briefly,duration each were then obtained by spontaneous void-
ing for the determination of baseline glomerular filtra- serum samples and calibrators (20 ml) were allowed
to react with a synthetic peptide (200 ml) in a 96-welltion rate (GFR) and renal plasma flow (ERPF). At the
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Table 2. Baseline renal hemodynamic and excretory valuesTable 1. Baseline values
Genotype Genotype
AA AC/CC AA AC/CC
Parameter (N 5 30) (N 5 36) P valueParameter (N 5 30) (N 5 36) P value
Male/female 22/8 28/8 NS GFR ml/min/1.73 m2 11364 105 63 0.04
ERPF ml/min/1.73 m2 642626 535 628 0.04Age years 2861 2761 NS
BMI kg/m2 2461 2561 NS RBF ml/min/1.73 m2 1103637 924 639 0.04
FF 0.2060.01 0.17 60.005 0.01UNa mmol/day 228630 197614 NS
Uurea mmol/day 359627 389625 NS RVR mm Hg/liter/min 7863 90 65 0.01
UNaV lmol/min 383631 346 644 NSSerum ACE U/liter 3964 4163 NS
Ang II pg/ml 1262 1162 NS Abbreviations are: GFR, glomerular filtration rate; ERPF, renal plasma flow;
PRA ng Ang I/liter/second 0.2860.04 0.3060.03 NS RBF, renal blood flow; FF, filtration fraction; RVR, renal vascular resistance;
MAP mm Hg 8862 8762 NS UNaV, urinary sodium excretion.
Hct 0.40660.009 0.40660.008 NS
Abbreviations are: BMI, body mass index; UNa, 24-hour urine sodium excre-
tion; Uurea, 24-hour urine urea excretion; ACE, angiotensin-converting enzyme;
Ang II, angiotensin II; PRA, plasma renin activity; MAP, mean arterial pressure;
Hct, hematocrit. Statistical analysis
Subjects were segregated into subgroups on the basis
of the presence or absence of the C allele (AA vs. AC/CC).
Data are presented as mean 6 sem. A between-groupmicroplate. The enzyme kinetics at 378C was followed
comparison of all parameters at baseline was made usingby the decrease in absorbance at 340 nm for 15 minutes
nonparametric methods (Wilcoxin rank sum test). Dif-with a Bio-Tek microplate reader (model #Ceres UV
ferences in within-subject and between-group responses900 Hdi). Blood for determination of Ang II was col-
to losartan and Ang II were determined by two-waylected into prechilled tubes containing ethylenediamine-
repeated-measures analysis of variance (ANOVA) andtetraacetic acid (EDTA) and angiotensinase inhibitor
Bonferroni correction. All statistical analyses were per-(0.1 ml Bestatin solution; Buhlmann Laboratories). Sam-
formed using the statistical package SAS (SAS Instituteples were analyzed using a competitive radioimmunoas-
Inc., Cary, NC, USA).say kit supplied by Buhlmann Laboratories AG.
Polymerase chain reaction. Genomic DNA was ex-
tracted from peripheral blood leukocytes as previously
RESULTS
described [14, 17]. The DNA was resuspended in 10 mm
Subject characteristicsTris-HCl, 0.2 mm sodium EDTA, pH 7.5, and the concen-
tration was determined by spectrophotometry. To deter- Sixty-six normal subjects were segregated into groups
on the basis of the presence or absence of the C allelemine the AGT1R genotype of the subjects, 0.1 mg of
of the AGT1R gene. Thirty subjects displayed the AAgenomic DNA was subjected to polymerase chain reac-
genotype. Twenty-nine subjects displayed the AC geno-tion (PCR) amplification [17]. The reaction mixture (20
type, and seven subjects displayed the CC genotype.ml) contained 50 mm KCl, 10 mm Tris, pH 8.3, 1.5 mm
Therefore, 36 subjects comprised the second group car-MgCl2, 1 mmol of each primer, 200 mmol of deoxy-ATP,
rying the C allele. As can be seen from Table 1, noGTP, CTP, TTP, gelatin 200 mg/ml, and 1 U of Taq
significant differences existed in proportion of females,polymerase. Thirty cycles of PCR were performed: 1
age, body mass index, urine sodium excretion, urine ureaminute at 958C, 1 minute at 558C, and 1.5 minutes at 728C.
excretion, serum ACE and Ang II levels, plasma reninThe primers were 59GCACCATGTTTTGAGGTT 39
activity, MAP, or Hct.and 59CGACTACTGCTTAGCATA 39. This PCR am-
plification yields a 546 bp product. The amplicon was
Baseline hemodynamic, humoral and renalsubjected to overnight incubation with Ddel at 378C, and
excretory functionthe digestion products were separated by electrophoresis
on 1.5% agarose gels containing ethidium bromide. The As shown in Table 2, the AC/CC subgroup exhibited
1166C AGT1R allele contains a recognition site for the significantly lower baseline values for GFR, ERPF, and
RBF, and significantly higher values for FF and RVR.restriction endonuclease, Ddel, so that digestion of the
PCR product with Ddel yields 435 bp and iii bp frag- Baseline values for MAP did not differ between sub-
groups nor did the urine sodium excretion (UNaV). Aldo-ments. The 1166A AGT1R allele does not contain a recog-
nition site for the restriction endonuclease, Ddel, so that sterone, although numerically increased in the AC/CC
genotype subgroup, did not differ significantly (316 6the 546 bp amplicon remains unaltered after incubation
with Ddel [18, 19]. 44 vs. 188 6 24 pmol/liter, P 5 NS).
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Fig. 1. Response of mean arterial pressure (DMAP) to losartan at two
and three hours after administration in the AA genotype subgroup (h)
and the AC/CC genotype subgroup (j). *P , 0.05 vs. baseline; †P , Fig. 2. Response of glomerular filtration rate (DGFR) to losartan at
0.05 vs. response of AA genotype subgroup. two and three hours after administration in the AA genotype subgroup
(h) and the AC/CC genotype subgroup (j). *P , 0.05 vs. baseline;
†P , 0.05 vs. response of AA genotype subgroup.
Hemodynamic, humoral, and renal excretory response
to losartan
hours (P 5 NS vs. baseline), and the AC/CC subgroup
The GFR response to losartan differed significantly value was 924 6 39 ml/min/1.73 m2 at baseline, 981 6
between subgroups, with the AA group remaining stable 71 at two hours, and 1000 6 60 at three hours (P 5 NS
(113 6 4 ml/min/1.73 m2 at baseline, 114 6 6 at 2 hours vs. baseline, P 5 NS vs. response of AA subgroup).
and 112 6 6 at 3 hours post-dose, P 5 NS vs. baseline) No significant differences were noted between sub-
and the AC/CC group exhibiting a pronounced increase groups in the FF response in that the AA subgroup value
in GFR from 105 6 3 ml/min/1.73 m2 at baseline to 116 6 5 was 0.17 6 0.005 at baseline, 0.18 6 0.01 at two hours,
at two hours and 112 6 9 at three hours (P 5 0.001 and 0.17 6 0.01 at three hours (P 5 NS vs. baseline),
vs. baseline, P 5 0.03 vs. response of AA group). The and the AC/CC subgroup value was 0.20 6 0.01 at base-
response of MAP also differed significantly between ge- line, 0.20 6 0.01 at two hours, and 0.19 6 0.01 at three
notype subgroups. The AA subgroup did not experience hours (P 5 NS vs. baseline, P 5 NS vs. response of AA
a significant decline in arterial pressure (83 6 2 mm Hg subgroup). Similar to the FF response, no significant
at baseline, 82 6 2 at 2 hours, and 83 6 3 at 3 hours differences were found between subgroups in the RVR
postdose, P 5 NS vs. baseline), whereas the AC/CC sub- response in that the AA subgroup value was 78 6 3 mm
group experienced a pressure decline that, although only Hg/liter/min at baseline, 79 6 3 at two hours, and 81 6
mild in magnitude, was statistically significant (85 6 1 5 at three hours (P 5 NS vs. baseline), and the AC/CC
mm Hg at baseline, 80 6 1 at 2 hours, and 80 6 2 at 3 subgroup value was 90 6 5 mm Hg/liter/min at baseline,
hours, P 5 0.02 vs. baseline, P 5 0.04 vs. response of 94 6 7 at two hours, and 88 6 7 at three hours (P 5
AA subgroup). NS vs. baseline, P 5 NS vs. response of AA subgroup).
No significant differences were discernible between sub- There was a significant difference between groups in
groups in the ERPF response in that the AA subgroup the aldosterone response to losartan. The AA subgroup
value was 642 6 26 ml/min/1.73 m2 at baseline, 629 6 value was 188 6 24 pmol/liter at baseline, 131 6 17 at
27 at two hours, and 635 6 38 at three hours (P 5 NS two hours, and 108 6 14 at three hours (P 5 NS vs.
vs. baseline), and the AC/CC subgroup value was 535 6 baseline) compared with the AC/CC group, which exhib-
28 ml/min/1.73 m2 at baseline, 577 6 41 at two hours, ited a significant decline from 316 6 44 pmol/liter at
and 593 6 33 at three hours (P 5 NS vs. baseline, P 5 baseline to 152 6 11 at two hours and 128 6 15 at three
NS vs. response of AA subgroup). In parallel with the hours (P 5 0.001 vs. baseline, P 5 0.03 vs. response of
observations on ERPF, no significant differences were AA subgroup). As expected, urinary sodium excretion
discernible between subgroups in the RBF response. The rates were similar in both genotype subgroups. No sig-
AA subgroup value was 1103 6 37 ml/min/1.73 m2 at nificant differences were found between subgroups in
the UNaV response, in that the AA subgroup value wasbaseline, 1064 6 39 at two hours, and 1082 6 72 at three
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Fig. 4. Glomerular filtration rate (GFR) at baseline and during angio-
tensin II infusion at 0.5 ng/kg/min in the AA genotype subgroup (h)
and the AC/CC genotype subgroup (j). *P , 0.05 vs. baseline; †P ,
0.05 vs. baseline value in AA genotype subgroup; §P , 0.05 vs. response
Fig. 3. Response of aldosterone (Daldosterone) to losartan at two and of AA genotype subgroup.
three hours after administration in the AA genotype subgroup (h) and
the AC/CC genotype subgroup (j). *P , 0.05 vs. baseline; †P , 0.05
vs. response of AA genotype subgroup.
58 ml/min/1.73 m2 at baseline and 779 6 60 during the
infusion (P 5 0.002 vs. baseline), and the AC/CC sub-
group value was 1001 6 41 ml/min/1.73 m2 at baseline383 6 31 mmol/min at baseline, 316 6 32 at two hours,
and 754 6 32 during the infusion (P 5 0.01 vs. baseline,and 359 6 40 at three hours (P 5 NS vs. baseline), and
P 5 NS vs. response of AA subgroup).the AC/CC subgroup value was 391 6 35 mmol/min at
No significant differences were noted between sub-baseline, 315 6 29 at two hours, and 305 6 27 at three
groups in the FF response in that the AA subgroup valuehours (P 5 NS vs. baseline, P 5 NS vs. response of AA
was 0.19 6 0.01 at baseline and 0.21 6 0.01 during thesubgroup). The MAP, GFR, and aldosterone responses
infusion (P 5 0.04 vs. baseline), and the AC/CC sub-to losartan are illustrated in Figures 1–3.
group value was 0.18 6 0.01 at baseline and 0.22 6 0.01
during the infusion (P 5 0.005 vs. baseline, P 5 NSHemodynamic, humoral, and renal excretory response
vs. response of the AA subgroup). Similar to the FFto angiotensin II
response, no significant differences were found betweenThe GFR response to Ang II differed significantly
subgroups in the RVR, the UNaV, or the aldosteronebetween subgroups (Fig. 4), with the AA group declining
responses to Ang II infusion.significantly from 120 6 4 ml/min/1.73 m2 at baseline to
100 6 8 by the end of the infusion period (P 5 0.001 vs.
baseline) and the AC/CC group remaining stable (102 6 3 DISCUSSION
to 98 6 4 ml/min/1.73 m2, P 5 NS, vs. baseline, P 5 0.03 This study was designed first to test the hypothesis that
vs. response of AA group). The response of MAP did genetic factors influence renal hemodynamic function.
not differ significantly between genotype subgroups. The Specifically, we hypothesized that a polymorphism of the
AA subgroup did not experience an increase in arterial AGT1R gene would be associated with lower values for
pressure (86 6 2 mm Hg at baseline and 88 6 2 during GFR in normal subjects. We chose to study the AGT1R
the Ang II infusion, P 5 NS) nor did the AC/CC sub- A1166→C polymorphism of the AGT1R gene because
group (88 6 2 mm Hg at baseline and 89 6 2 during the Bonnardeaux et al showed that the C allele was increased
Ang II infusion, P 5 NS). in frequency in a case control study of hypertensive pa-
No significant differences were discernible between tients [9]. Subsequent studies by this group have related
subgroups in the ERPF response in that the AA sub- the C allele to aortic stiffness [10] and increased risk of
group value was 646 6 34 ml/min/1.73 m2 at baseline myocardial infarction [11].
and 477 6 35 during the infusion, P 5 0.004 vs. baseline), In order to test our hypothesis, we genotyped subjects
and the AC/CC subgroup value was 570 6 24 ml/min/ for the AGT1R A1166→C polymorphism and then divided
1.73 m2 at baseline and 448 6 18 during the infusion (P 5 the subjects onto two groups based on the presence of
0.001 vs. baseline, P 5 NS vs. response of AA subgroup). the C allele (AA and AC/CC). We then compared base-
In parallel with the observations on ERPF, no significant line renal and peripheral hemodynamic function between
differences were discernible between subgroups in the the groups. In order to control for confounding variables,
all subjects were counseled by a research dietitian andRBF response in that the AA subgroup value was 1082 6
Miller et al: Ang II receptor polymorphism and renal function2178
were prescribed a controlled diet. Because Du et al have as in our study, remains unknown. The A1166→C polymor-
phism is in the 39 untranslated region of the AGT1Rreported that renal AGT1R mRNA levels are increased
by a low-sodium diet [20], subjects adhered to a 200 gene and is therefore not a coding polymorphism that
influences ligand binding or receptor signaling [9]. It ismmol sodium diet [14]. Urinary sodium excretion rates
were measured and found to be similar between the two possible that the polymorphism is in linkage disequilib-
rium with a functional polymorphism of the gene pro-groups. Because protein intake can influence the activity
of the RAS [21] as well as increase GFR [22, 23], the moter, as has recently been discovered for the M235T
angiotensinogen polymorphism [28], or alternatively, el-subjects were also prescribed a diet containing 1.5 to 2.0
g of protein per kg body wt. A 24-hour urine collection, ements in the 39 untranslated region that influence tran-
script stability [29]. Finally, it is also possible that theobtained prior to study, confirmed similar urinary urea
excretion rates in the two groups. AGT1R A1166→C polymorphism is a marker for a nearby
gene. Any of these mechanisms could account for theOur first major observation was that baseline values
for renal hemodynamic function differed between groups. observed responses, but they remain hypothetical.
Our findings regarding the aldosterone responses toSubjects in the AC/CC group exhibited significantly
lower mean values for GFR, ERPF, and RBF compared the experimental maneuvers deserve comment. Similar
to other studies [30], we were able to demonstrate awith subjects homozygous for the A allele. Values for
MAP did not differ between the groups so that lower reduction in plasma aldosterone concentrations after lo-
sartan administration in our subjects, a response thatvalues for ERPF and RBF in the AC/CC group reflected
increased RVR. Myers, Deen, and Brenner were the was independent of genotype. In another study, Hopkins
et al examined the relationship between M235T geno-first to show that infusion of Ang II into normal rats
lowers GFR [24], whereas more recently, Allon, Pasque, type and aldosterone plasma concentrations in hyperten-
sive and normotensive volunteers on a controlled sodiumand Rodriguez have reported that the ACE inhibitor
captopril increases the GFR in normal human subjects diet and were unable to discern a genotypic effect [31].
Despite the fact that we demonstrated a numeric differ-[25]. Taken together, these studies suggest that intrarenal
Ang II activity is an important determinant of intrarenal ence between genotype subgroups in aldosterone values,
our data do not demonstrate a significant relationshipvascular resistance in normal subjects. Thus, our obser-
vation of differences in renal hemodynamic function in between AGT1R A1166→C polymorphism and baseline
plasma concentrations of aldosterone. It is apparent,patients segregated on the basis of AGT1R polymor-
phism could have been due to an increase in intrarenal however, that the response to losartan administration
was more pronounced in those with the C allele, andAng II activity in the AC/CC subjects.
Our study, therefore, was also designed to test the these results support our hypothesis that the AGT1R C
allele is related to increased Ang II activity. It is interest-hypothesis that intrarenal Ang II activity was increased
in the AC/CC group compared with the AA group. To ing to note that we did not discern a losartan-mediated
increase in sodium excretion in the AC/CC group, eventest this hypothesis, the renal and peripheral hemody-
namic response to AGT1R blockade with losartan was though there was a rise in GFR and decline in aldoste-
rone. Many factors affect sodium excretion, and in thiscompared in the two groups. Our second major observa-
tion was that subjects in the AC/CC group exhibited case, it is possible that such an increase was countered
by the decline in arterial pressure, but this cannot besignificant decreases in MAP and increases in GFR after
AGT1R blockade. In contrast, values for GFR and MAP proven from this protocol.
The infusion studies were performed in order to deter-were unchanged after losartan administration in subjects
homozygous for the A allele. The response to losartan mine if there was an association between the AGT1R
A1166→C polymorphism and the renal and systemic he-in the AC/CC group occurred even though all of the
subjects were sodium replete and the studies were per- modynamic response to the receptor ligand, Ang II. Each
group of patients exhibited declines in RBF and in-formed supine, both of which are conditions expected
to blunt the hemodynamic response to AGT1R blockade creases in RVR in response to Ang II, but subjects in
the AC/CC group maintained GFR despite declines in[26]. These studies support our hypothesis that intrarenal
Ang II activity is increased in the AC/CC group. RBF. Although the result was not significantly different
between groups, there appeared to be a more pro-Previous studies have investigated the role of the
AGT1R A1166→C polymorphism in the hemodynamic re- nounced numerical increase in the FF in the AC/CC
subgroup. The mechanism responsible for the mainte-sponse to antihypertensive medications, and in accord
with our work, Benetos et al found that the ACE inhibi- nance of GFR in the AC/CC group was not determined,
but an attractive hypothesis is that pharmacological Angtor perindopril has a greater effect on aortic stiffness
in individuals with the C allele [27]. The mechanism II led to a greater increase in efferent arteriolar resis-
tance in the AC/CC group. Additional mechanisms mayresponsible for the association between the polymor-
phism and the hemodynamic response to RAS blockade, be proposed. For example, the regulation of receptor
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